GGrantIndex
← Search

Cancer Center Support Grant

$60,000P30FY2020CANIH

Wayne State University, Detroit MI

Investigators

Linked publications, trials & patents

Trial NCT06501040Trial NCT04479267Trial NCT04397679Trial NCT04266522Trial NCT04159896Trial NCT03875053Trial NCT03683420Trial NCT03456804Trial NCT03454529Trial NCT03453489Trial NCT03406858Trial NCT03252600Trial NCT03147885Trial NCT02824029Trial NCT02819024Trial NCT02723604Trial NCT02620865Trial NCT02568449Trial NCT02521090Trial NCT02520115Trial NCT02472275Trial NCT02470559Trial NCT02359019Trial NCT02178436Trial NCT02178163Trial NCT02173093Trial NCT02145078Trial NCT02094872Trial NCT02058706Trial NCT02037256Trial NCT01987596Trial NCT01958372Trial NCT01698658Trial NCT01504711Trial NCT01281163Trial NCT01175980Trial NCT01147016Trial NCT01116232Trial NCT01071564Trial NCT01051570Trial NCT01022138Trial NCT00984919Trial NCT00972023Trial NCT00942422Trial NCT00938626Trial NCT00935090Trial NCT00918762Trial NCT00914147Trial NCT00906503Trial NCT00903214Trial NCT00899665Trial NCT00897910Trial NCT00897741Trial NCT00897494Trial NCT00897247Trial NCT00890617Trial NCT00888654Trial NCT00769288Trial NCT00768118Trial NCT00717535Trial NCT00691015Trial NCT00559897Trial NCT00541099Trial NCT00527124Trial NCT00521261Trial NCT00520767Trial NCT00514215Trial NCT00503841Trial NCT00499694Trial NCT00482846Trial NCT00459121Trial NCT00438204Trial NCT00423826Trial NCT00410904Trial NCT00376948Trial NCT00369109Trial NCT00305747Trial NCT00303901Trial NCT00301808Trial NCT00293384Trial NCT00288028Trial NCT00258466Trial NCT00258310Trial NCT00258284Trial NCT00258245Trial NCT00258232Trial NCT00248560Trial NCT00248482Trial NCT00244946Trial NCT00244933Trial NCT00243048Trial NCT00238329Trial NCT00227721Trial NCT00217581Trial NCT00121264Trial NCT00118157Trial NCT00078923Trial NCT00068653Trial NCT00066326Trial NCT00056004

Abstract

? DESCRIPTION (provided by applicant): The Tumor Biology and Microenvironment (TBM) Program aims to eradicate cancer by identifying the cellular and molecular mechanisms that drive interactions between tumors and their microenvironments, and develop and test innovative diagnostic and treatment strategies. This highly integrated program includes 36 members from 16 WSU departments and $14,193,608 in grants, of which $5,908,215 is peer reviewed. The Program goals are addressed with three themes that encompass basic, preclinical, and clinical research. The first theme identifies and exploits the mechanisms that confer phenotypical plasticity and survival of tumor cells in tumor progression. Translational research is conducted to evaluate the potential clinical application of these molecular determinants as tumor markers and/or therapeutic targets. The second theme identifies and exploits the mechanisms that confer the unhealable wounding of tumor stroma. Our investigators identify and characterize factors in an extracellular proteolysis and signaling network that enable tumor cells to adapt to and subvert the microenvironment in the development of bone metastases. Key molecules in this network are evaluated to determine if they can be used to predict cancer progression and treatment outcomes. The third theme identifies and exploits the host immune response to tumor progression. Bispecific antibody-armed activated T-cells are tested in solid tumors and hematologic malignancies in the context of chemotherapy or high dose chemotherapy and stem cell transplantation. Anti-tumor DNA vaccines are developed and tested using mouse and domesticated cat models. Our investigators study immune modulators and inhibitors of adverse pro-inflammatory responses. Our members also develop novel vehicles to deliver immunotherapeutic agents. TBM Program members actively collaborate with members of the MI, MT, and PSDR Programs at KCI. Of the 612 manuscripts published from December 2010 to November 2014, 44% and 38% were intra- and inter-programmatic, respectively, and 27% were multi-institutional collaborations.

View original record on NIH RePORTER →